Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma.

@article{Persons2000AmplificationAO,
  title={Amplification and overexpression of HER-2/neu are uncommon in advanced stage melanoma.},
  author={Diane L. Persons and Daniel Alan Arber and Jeffrey A. Sosman and K A Borelli and Marilyn L. Slovak},
  journal={Anticancer research},
  year={2000},
  volume={20 3B},
  pages={1965-8}
}
The HER-2/neu proto-oncogene is a useful prognostic and predictive biomarker in breast cancer. In addition, use of a humanized monoclonal antibody against HER-2/neu has recently been shown to have efficacy in the treatment of metastatic breast cancer. In order to examine the potential of HER-2/neu as a biomarker and as a target for HER-2/neu monoclonal antibody treatment in melanoma, we examined the HER-2/neu status in 40 advanced stage melanomas. Using fluorescence in situ hybridization for… CONTINUE READING